BYSANTI

Launch

milsaperidone

Vanda Pharmaceuticals
NDAORALTABLET
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
1

Clinical Trials (1)

NCT06830044Phase 3Recruiting

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Started Mar 2025
500 enrolled
Major Depressive Disorder (MDD)
Company
VP
Vanda Pharmaceuticals
WASHINGTON, DC
External Resources
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers